Cancer News and Research

Latest Cancer News and Research

Cardiologist provides heart-healthy tips for women

Heart disease is the single leading cause of death for American women. Nearly twice as many women in the United States die of heart disease, stroke and other cardiovascular diseases than from all forms of cancer, including breast cancer.

30 Jan 2010

Scientists currently working on 861 new cancer medicines

The Bienville Democrat in Arcadia, LA recently reported that America's pharmaceutical research and biotechnology companies have made great progress in treating cancers, introducing many new, breakthrough medicines.

30 Jan 2010

sigma-tau Group acquires Enzon’s specialty pharmaceutical business

Enzon Pharmaceuticals, Inc. ("Enzon") announced today that it has closed the sale of its specialty pharmaceutical business to the sigma-tau Group ("sigma-tau"). Enzon is a biopharmaceutical company dedicated to the discovery and development of important medicines for patients with cancer and other life-threatening conditions. Enzon's business now consists of its royalties, Peg SN38, LNA and PEG technology platforms.

30 Jan 2010

Breast cancer patient battles insurer; Recession burdens charity clinics

News outlets report on a patient's struggle to get coverage for cancer treatment and over-burdened charity clinics.

30 Jan 2010

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

30 Jan 2010

Surgeon General's report lays out recommendations to address childhood obesity

"As many as one in three children are overweight or obese, according to a new report" released yesterday by U.S. Surgeon General Regina Benjamin.

30 Jan 2010

Docking algorithm EADock allows successful design of new inhibitors for anti-cancer target

Many human tumors express indoleamine 2,3-dioxygenase (IDO), an enzyme which mediates an immune-escape in several cancer types. Researchers in the Molecular Modeling group at the SIB Swiss Institute of Bioinformatics and Dr. Beno-t J. Van den Eynde's group at the Ludwig Institute for Cancer Research Ltd (LICR) Brussels Branch developed an approach for creating new IDO inhibitors by computer-assisted structure-based drug design. The study was presented in the January 2010 online issue of the Journal of Medicinal Chemistry.

30 Jan 2010

Rubicon Genomics reaches agreement with ZyGEM to market its PicoPlex single-cell amplification kits

Rubicon Genomics, Inc., a developer of pre-analytical amplification products that enable more comprehensive genetic analysis of clinical and research samples, announced today that it has reached agreement with ZyGEM to non-exclusively market Rubicon's PicoPlex™ single-cell amplification kits in Australia and New Zealand.

30 Jan 2010

$Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia$

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of perifosine (KRX-0401) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of the Journal of Clinical Cancer Research.

30 Jan 2010

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.

29 Jan 2010

Diffusion Pharmaceuticals closes on $5.9M in additional private financing

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.

29 Jan 2010

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.

29 Jan 2010

New mathematical model helps in predicting treatment outcomes for cervical cancer patients

Cervical cancer is highly curable when caught early. But in a third of cases, the tumor responds poorly to therapy or recurs later, when cure is much less likely.

29 Jan 2010

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.

29 Jan 2010

Quantrx Biomedical signs agreement to acquire NuRx Pharmaceuticals

QuantRx Biomedical Corporation today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc. (OTCBB: NUXP). The transaction is structured as a tax-free, all stock acquisition resulting in a combined company with no debt and a simplified ownership and capital structure.

29 Jan 2010

First Edition: January 29, 2010

Today's news highlights the Democrats' continuing struggle to find a way forward on health reform.

29 Jan 2010

ASH offers hematologists a new resource for earning CME credits

The American Society of Hematology (ASH) now offers physicians who diagnose and treat blood disorders a new resource for earning continuing medical education (CME) credits while staying abreast of the latest clinical strategies in the rapidly changing field of hematology.

29 Jan 2010

ECCO supports its member organisations' proposals for adapting the EU Clinical Trials Directive

In response to a European Commission consultation on the EU Clinical Trials Directive, ECCO - the European CanCer Organisation - has supported proposals by its member organisations for adapting the Directive's requirements to reflect practical necessities in cancer research and treatment.

29 Jan 2010

ChromoCure retains Patent & Intellectual Property Attorneys to assess its Intellectual Property portfolio

ChromoCure, Inc. -- The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections.

29 Jan 2010

BBVA Foundation Frontiers of Knowledge Award granted to Robert J. Lefkowitz

The BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category goes in this second edition to Prof. Robert J. Lefkowitz (1943, New York, United States), investigator in the Department of Medicine at Duke University (United States).

29 Jan 2010

Cancer News and Research

Latest Cancer News and Research

Cardiologist provides heart-healthy tips for women

Scientists currently working on 861 new cancer medicines

sigma-tau Group acquires Enzon’s specialty pharmaceutical business

Breast cancer patient battles insurer; Recession burdens charity clinics

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

Surgeon General's report lays out recommendations to address childhood obesity

Docking algorithm EADock allows successful design of new inhibitors for anti-cancer target

Rubicon Genomics reaches agreement with ZyGEM to market its PicoPlex single-cell amplification kits

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

Diffusion Pharmaceuticals closes on $5.9M in additional private financing

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

New mathematical model helps in predicting treatment outcomes for cervical cancer patients

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

Quantrx Biomedical signs agreement to acquire NuRx Pharmaceuticals

First Edition: January 29, 2010

ASH offers hematologists a new resource for earning CME credits

ECCO supports its member organisations' proposals for adapting the EU Clinical Trials Directive

ChromoCure retains Patent & Intellectual Property Attorneys to assess its Intellectual Property portfolio

BBVA Foundation Frontiers of Knowledge Award granted to Robert J. Lefkowitz

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in